<DOC>
	<DOCNO>NCT00535470</DOCNO>
	<brief_summary>To evaluate efficacy safety topical application MCH 0.04 % propylene glycol ointment ( PG ) patient stage I IIA MF previously treat MCH 0.02 % PG AP ointment achieve complete response .</brief_summary>
	<brief_title>An Open Label Study Evaluate Safety Efficacy Mechlorethamine ( MCH ) 0.04 % Formulation Mycosis Fungoides</brief_title>
	<detailed_description>This multi-center , open-label study patient previously treat stage I ( IA IB ) IIA MF receive complete response complete 12 month treatment clinical trial ( 2005NMMF-201-US ) either 0.02 % MCH PG 0.02 % MCH Aquaphor ( AP ) ointment formulation .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<criteria>Patients must complete treatment phase Yaupon Therapeuticssponsored Phase II Pivotal study MCH 0.02 % either PG AP formulation achieve complete response . Pregnant nursing female , male female childbearing potential , use effective mean contraception</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>